Seaport Therapeutics is a technology company.
Seaport Therapeutics has raised $330.0M across 2 funding rounds.
Seaport Therapeutics has raised $330.0M in total across 2 funding rounds.
Seaport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel neuropsychiatric medicines for areas of high unmet patient needs, such as depression, anxiety, and schizophrenia.[1][2][4] It builds a pipeline of first- and best-in-class oral therapies powered by its proprietary Glyph technology platform, which enables oral bioavailability, bypasses first-pass metabolism, and reduces hepatotoxicity and other side effects for clinically validated mechanisms previously limited by delivery challenges.[1][2][4][6] The company serves patients with neuropsychiatric disorders, addressing problems like debilitating side effects of existing treatments by advancing safer, more effective options; it demonstrates growth momentum through recent presentations at investor conferences, investments from firms like General Atlantic in 2024, and a team with a track record of FDA-approved drugs like Cobenfy (formerly KarXT).[2][5][6]
Seaport Therapeutics was founded by Daphne Zohar, who serves as CEO and Board Member, building on her prior success at PureTech Health, where she co-founded entities including Karuna Therapeutics—acquired by Bristol Myers Squibb for $14 billion in 2024 after developing Cobenfy (KarXT), the first new schizophrenia drug class in over 50 years.[3][6] The idea emerged from Zohar's experience inventing and advancing neuropsychiatric medicines at PureTech, where her team achieved clinical success rates six times the industry average, including KarXT's three pivotal studies leading to FDA approval in September 2024.[3][6] Early traction stems from this proven strategy: leveraging clinically validated mechanisms held back by pharmacokinetic issues, now unlocked via the Glyph platform, with the company launching in 2024 amid strong investor backing like General Atlantic.[5][6]
Seaport rides the wave of innovation in neuropsychiatry, targeting a market plagued by inadequate treatments—e.g., schizophrenia's first new mechanism in 50+ years via KarXT, now commercialized as Cobenfy, highlighting demand for side-effect-free options amid rising mental health crises.[6] Timing is ideal post-2024 Karuna acquisition and FDA approval, fueling investor confidence in de-risked pipelines; market forces like aging populations, post-pandemic anxiety/depression surges, and biopharma's shift to oral small molecules favor Seaport's platform.[2][3][6] It influences the ecosystem by validating PureTech-style "invention labs," accelerating clinically proven ideas via tech platforms, and setting benchmarks for biotech efficiency in high-unmet-need areas.[3]
Seaport is poised for pipeline milestones, with Glyph-enabled candidates advancing into clinical trials for depression and anxiety, potentially mirroring KarXT's path to blockbuster status and partnerships/acquisitions.[2][4][6] Trends like AI-driven drug design and oral CNS breakthroughs will amplify its edge, while mental health funding booms could drive rapid scaling. Its influence may evolve from niche innovator to category leader, much like Karuna, tying back to its core strength: turning validated science into patient wins via smart tech.
Seaport Therapeutics has raised $330.0M in total across 2 funding rounds.
Seaport Therapeutics's investors include General Atlantic, venBio, ARCH Venture Partners, DeepWork Capital, Sofinnova Investments, Mike Moradi.
Seaport Therapeutics has raised $330.0M across 2 funding rounds. Most recently, it raised $230.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $230.0M Series B | General Atlantic, venBio | |
| Apr 1, 2024 | $100.0M Series A | ARCH Venture Partners, DeepWork Capital, General Atlantic, Sofinnova Investments, Mike Moradi |